FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014
Drug reviews will include a benefit-risk summary assessment that states the rationale for regulatory action on a drug or biologic application and explains how differences of opinion among reviewers were resolved.
You may also be interested in...
In finalizing a guidance on its approach to the fundamental benefit-risk assessment for new drug reviews, US FDA affirms the central role of the qualitative benefit-risk framework tool that was rolled out a decade ago.
Office of New Drug's chief of staff will become Amgen's director of global regulatory policy and R&D.
Agency summaries contained in reviews of novel drugs and biologics are useful and informative but difficult to find, and their use should be expanded to other types of applications, industry sponsors and other external stakeholders say.